Aerie Pharmaceuticals, Inc. - Product Pipeline Review - 2012

Global Markets Direct, July 2012, Pages: 35

Aerie Pharmaceuticals, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Aerie Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the Aerie Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Aerie Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Aerie Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Aerie Pharmaceuticals, Inc. - Brief Aerie Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Aerie Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Aerie Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Aerie Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Aerie Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Aerie Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Aerie Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Aerie Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Aerie Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Aerie Pharmaceuticals, Inc.; Aerie Pharmaceuticals, Inc. - Key Therapeutics; Aerie Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Aerie Pharmaceuticals, Inc. - News; Aerie Pharmaceuticals, Inc. - Latest Updates; Aerie Pharmaceuticals, Inc. - Pipeline; Aerie Pharmaceuticals, Inc. - Discontinued/Dormant Projects

2
List of Tables 4
List of Figures 4
Aerie Pharmaceuticals, Inc. Snapshot 5
Aerie Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Aerie Pharmaceuticals, Inc. – Research and Development Overview 6
Key Therapeutic Areas 6
Aerie Pharmaceuticals, Inc. – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Pipeline Products – Combination Treatment Modalities 10
Aerie Pharmaceuticals, Inc. – Pipeline Products Glance 11
Aerie Pharmaceuticals, Inc. Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Aerie Pharmaceuticals, Inc. – Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
Aerie Pharmaceuticals, Inc. – Drug Profiles 13
AR-12286 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
AR-12286 + Latanoprost 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
AR-12286 + Travoprost 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
AR-13165 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
AR-13324 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Aerie Pharmaceuticals, Inc. – Pipeline Analysis 18
Aerie Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class 18
Aerie Pharmaceuticals, Inc. – Pipeline Products By Target 19
Aerie Pharmaceuticals, Inc. – Pipeline Products by Route of Administration 20
Aerie Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action 21
Aerie Pharmaceuticals, Inc. – Recent Pipeline Updates 22
Aerie Pharmaceuticals, Inc. - Dormant Projects 23
Aerie Pharmaceuticals, Inc. – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Financial Deals Landscape 25
Aerie Pharmaceuticals, Inc., Deals Summary 25
Aerie Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details 26
Venture Financing 26
Aerie Pharma Secures $30 Million In Series B Financing Round 26
Aerie Pharma Secures $41.3 Million In Venture Financing 28
Aerie Pharma Secures $5.25 Million In Venture Financing 30
Aerie Pharma Raises $10 Million In Series B Financing 31
Aerie Pharma Secures $21 Million In Series A Financing 32
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35

List of Tables
Aerie Pharmaceuticals, Inc., Key Information 5
Aerie Pharmaceuticals, Inc., Key Facts 5
Aerie Pharmaceuticals, Inc. – Pipeline by Indication, 2012 7
Aerie Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012 8
Aerie Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012 9
Aerie Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012 10
Aerie Pharmaceuticals, Inc. – Phase II, 2012 11
Aerie Pharmaceuticals, Inc. – Pre-Clinical, 2012 12
Aerie Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012 18
Aerie Pharmaceuticals, Inc. - Pipeline By Target, 2012 19
Aerie Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012 20
Aerie Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2012 21
Aerie Pharmaceuticals, Inc. – Recent Pipeline Updates, 2012 22
Aerie Pharmaceuticals, Inc. - Dormant Developmental Projects,2012 23
Aerie Pharmaceuticals, Inc., Other Locations 24
Aerie Pharmaceuticals, Inc., Deals Summary 25
Aerie Pharma Secures $30 Million In Series B Financing Round 26
Aerie Pharma Secures $41.3 Million In Venture Financing 28
Aerie Pharma Secures $5.25 Million In Venture Financing 30
Aerie Pharma Raises $10 Million In Series B Financing 31
Aerie Pharma Secures $21 Million In Series A Financing 32

List of Figures
Aerie Pharmaceuticals, Inc. – Pipeline by Indication, 2012 7
Aerie Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012 8
Aerie Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012 9
Aerie Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012 10
Aerie Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012 18
Aerie Pharmaceuticals, Inc. - Pipeline By Target, 2012 19
Aerie Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012 20
Aerie Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2012 21

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Idenix Pharmaceuticals, Inc.
• Scientific Games Corporation - Company Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• eBay - Strong Execution
• Ixia - Company Analysis
• Amazon - Point of Realization in 2013?
• SunGard - Profile - US
• Abbott Laboratories - IT Sales Opportunities - 2009